
    
      This is a 2 Period study. In Period 1, subjects will be assigned randomly to receive
      Advagraf® or Prograf® administered once or twice daily, respectively, for a period of 10
      days. In Period 2, subjects will be converted from Advagraf® to Prograf® or from Prograf® to
      Advagraf® for 10 additional days of dosing. Dose adjustments will be made based on the
      monitoring of drug levels in blood.
    
  